Učitavanje...
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Wit...
Spremljeno u:
| Izdano u: | Cancers (Basel) |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6827355/ https://ncbi.nlm.nih.gov/pubmed/31547040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11101404 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|